Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol versus placebo for breakthrough pain after fracture surgery
ACTRN12625001157460Phase 4Recruiting
- Sponsor
- University of New South Wales
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in acute postoperative pain and bone fracture (Fx) comparing Tapentadol breakthrough pain arm with Placebo breakthrough pain arm (2 arms). Primary endpoint: Pain intensity over the last week. Started May 2026; status: recruiting.
02
Drugs
tapentadol
03
Conditions
acute postoperative painbone fracture (Fx)
Beyond the preview
Go deeper on ACTRN12625001157460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001157460.